AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26989846 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine combination tablets (morning administration)
Number of subjects: 0
Study 26989846 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine combination tablets (both timings)
Number of subjects: 0
Study 24061071 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ)
Number of subjects: 26
Study 24061071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21448129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral weight loss intervention (22 group sessions over 26 weeks)
Number of subjects: 472
Study 21448129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral weight loss intervention
Number of subjects: 472
Study 20600809 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 60
Study 20600809 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 60
Study 20600809 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study 17959080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40
Study 17959080 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 40
Study 17959080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 16097900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 109
Study 16097900 — intervention group
Group type: COMPARATOR
Intervention: General health education (GHE)
Number of subjects: 109
Study 12073203 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits with reduced systemic heparinization
Number of subjects: 90
Study 12073203 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated circuits with full systemic heparinization
Number of subjects: 90
Study 12073203 — intervention group
Group type: COMPARATOR
Intervention: Conventional circuits with full systemic heparinization
Number of subjects: 90
Study 11899264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic painful tendinosis (Achilles, patellar, ECRB)
Number of subjects: 0
Study 9647875 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus radiotherapy
Number of subjects: 401
Study 9647875 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 401
Study 8011007 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained‐release metoclopramide (Cronoprimperan)
Number of subjects: 12
Study 8011007 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation (Primperan)
Number of subjects: 12
Study 8011007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 12
Study 2679289 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet or anticoagulant therapy, early initiation
Number of subjects: 0
Study 2679289 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 2679289 — intervention group
Group type: COMPARATOR
Intervention: Placebo or nonplacebo control
Number of subjects: 0
Study 766619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g hydrocortisone hemisuccinate
Number of subjects: 38
Study 766619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g hydrocortisone hemisuccinate
Number of subjects: 38
Study 766619 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g hydrocortisone hemisuccinate
Number of subjects: 38
Study 766619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline solution)
Number of subjects: 38
Study 7312235 — intervention group
Group type: COMPARATOR
Intervention: Conventional paracervical block (almost simultaneous injection of the 2 sides)
Number of subjects: 42
Study 7312235 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with a 10-minute interval between injections
Number of subjects: 42
Study 31567719 — intervention group
Group type: EXPERIMENTAL
Intervention: Full bench press (BPFULL)
Number of subjects: 50
Study 31567719 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thirds bench press (BP2/3)
Number of subjects: 50
Study 31567719 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third bench press (BP1/3)
Number of subjects: 50
Study 31567719 — intervention group
Group type: COMPARATOR
Intervention: Control (training cessation)
Number of subjects: 50
Study 31649322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased educational attainment (EA)
Number of subjects: 780000
Study 31394412 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-affirmation and goals task (VAG)
Number of subjects: 171
Study 31394412 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-affirmation task (VA)
Number of subjects: 171
Study 31394412 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmation control task (NAC)
Number of subjects: 171
Study 29794277 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (LDK) 1 mg/kg
Number of subjects: 240
Study 29794277 — intervention group
Group type: COMPARATOR
Intervention: IV morphine (MOR) 0.1 mg/kg
Number of subjects: 240
Study 25773139 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + BMMNC
Number of subjects: 42
Study 25773139 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 42
Study 24590745 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that thirdhand smoke is harmful
Number of subjects: 1947
Study 22455355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.25 g/kg)
Number of subjects: 24
Study 22455355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 24
Study 22455355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 24
Study 22455355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20471179 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivation/Stress group
Number of subjects: 47
Study 20471179 — intervention group
Group type: COMPARATOR
Intervention: Reactivation/No Stress group
Number of subjects: 47
Study 20471179 — intervention group
Group type: COMPARATOR
Intervention: No Reactivation/Stress group
Number of subjects: 47
Study 18240258 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNFα treatment in PsA
Number of subjects: 1268
Study 18240258 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNFα treatment in AS
Number of subjects: 1268
Study 18240258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFα treatment in RA
Number of subjects: 1268
Study 18240258 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant MTX in RA and PsA
Number of subjects: 1268
Study 18240258 — intervention group
Group type: COMPARATOR
Intervention: Concomitant MTX in AS
Number of subjects: 1268
Study 18240258 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQOL improvements in PsA and AS
Number of subjects: 1268
Study 15886531 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to decrease stroke risk in diabetic and hypertensive patients
Number of subjects: 0
Study 12442933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (intubation dose 0.1 mg kg(‐1))
Number of subjects: 30
Study 12442933 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.5 mg kg(‐1))
Number of subjects: 30
Study 12442933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (effective dose 0.05 mg kg(‐1))
Number of subjects: 30
Study 12442933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (repeat dose 0.02 mg kg(‐1))
Number of subjects: 30
Study 10350246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirilazad mesylate (15 mg/kg/day)
Number of subjects: 823
Study 10350246 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 823
Study 8961907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Number of subjects: 134
Study 8961907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 1756842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 22
Study 1756842 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline (placebo)
Number of subjects: 22
Study 6803633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 10
Study 6803633 — intervention group
Group type: COMPARATOR
Intervention: Control exercise challenges (no treatment)
Number of subjects: 10
Study 6803633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (pretreatment)
Number of subjects: 10
Study 28853296 — intervention group
Group type: EXPERIMENTAL
Intervention: Art participation sessions (n=41)
Number of subjects: 81
Study 28853296 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=40)
Number of subjects: 81
Study 29677164 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater adherence to the French nutritional recommendations (measured by PNNS‐GS)
Number of subjects: 2249
Study 29677164 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI status (mediator)
Number of subjects: 2249
Study 26555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz, 2000 pulses divided into 20 trains with one-sec inter-train interval)
Number of subjects: 24
Study 26555886 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 24
Study 26555886 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 24574935 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis-specific therapeutic exercise program
Number of subjects: 144
Study 24574935 — intervention group
Group type: COMPARATOR
Intervention: Observation for idiopathic scoliosis
Number of subjects: 144
Study 22931315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily) + Aspirin (325 mg daily)
Number of subjects: 3020
Study 22931315 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg daily)
Number of subjects: 3020
Study 20405783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 30% of isometric maximal voluntary contraction (MVC)
Number of subjects: 8
Study 20405783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction at 60% of isometric maximal voluntary contraction (MVC)
Number of subjects: 8
Study 20405783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both loads (30% and 60%)
Number of subjects: 8
Study 20405783 — intervention group
Group type: EXPERIMENTAL
Intervention: Load effect analysis
Number of subjects: 8
Study 18496993 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory steady state response (ASSR) thresholds at 500 and 2000 Hz with a 46 Hz modulation rate
Number of subjects: 0
Study 18496993 — intervention group
Group type: COMPARATOR
Intervention: Normal control group matched for age and hearing sensitivity
Number of subjects: 0
Study 16269927 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 25
Study 16269927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12860867 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 325
Study 12860867 — intervention group
Group type: COMPARATOR
Intervention: 40 mg simvastatin
Number of subjects: 325
Study 12860867 — intervention group
Group type: COMPARATOR
Intervention: Comparison between atorvastatin and simvastatin
Number of subjects: 325
Study 10365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin in normoglycaemia (200 mg intravenously)
Number of subjects: 12
Study 10365900 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin in hyperglycaemia (200 mg intravenously)
Number of subjects: 12
Study 10365900 — intervention group
Group type: COMPARATOR
Intervention: Placebo in normoglycaemia
Number of subjects: 12
Study 10150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy and long-term laser treatment for capsular glaucoma
Number of subjects: 0
Study 10150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for capsular glaucoma
Number of subjects: 0
Study 10150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular glaucoma
Number of subjects: 0
Study 2132565 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (leucovorin) supplementation given orally 4 hours after weekly low dose methotrexate administration
Number of subjects: 20
Study 2132565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6110536 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TBE-vaccination (purified TBE vaccine)
Number of subjects: 72
Study 6110536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 30419888 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience Curriculum (RESCUR)
Number of subjects: 1000
Study 30419888 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation in non-governmental organizations and social services groups
Number of subjects: 1000
Study 27518188 — intervention group
Group type: EXPERIMENTAL
Intervention: EVA Park intervention (daily language stimulation sessions for 5 weeks)
Number of subjects: 20
Study 27518188 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 20
Study 25457315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic locking screw (DLS) with MIPO bridging technique
Number of subjects: 20
Study 25457315 — intervention group
Group type: COMPARATOR
Intervention: Standard screws on both fracture sides
Number of subjects: 20
Study 22398566 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-1: pressure control ventilation for 1 min
Number of subjects: 25
Study 22398566 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-2: two hyperinflations with continuous positive airway pressure for 20 sec and 1 min interval in between
Number of subjects: 25
Study 22398566 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-3: three consecutive sighs
Number of subjects: 25
Study 20643015 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (5 mL of levobupivacaine hydrochloride, 25 mg/10 mL) soaked Merocele packs
Number of subjects: 41
Study 20643015 — intervention group
Group type: COMPARATOR
Intervention: Saline soaked Merocele packs
Number of subjects: 41
Study 18561542 — intervention group
Group type: EXPERIMENTAL
Intervention: Real articles (le, la, les, un, une, des)
Number of subjects: 0
Study 18561542 — intervention group
Group type: COMPARATOR
Intervention: Pseudo articles
Number of subjects: 0
Study 15777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 5mg
Number of subjects: 24
Study 15777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 10mg
Number of subjects: 24
Study 15777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 20mg
Number of subjects: 24
Study 15777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR (steady state)
Number of subjects: 24
Study 15777102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR (all doses)
Number of subjects: 24
Study 15777102 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone hydrochloride (coadministered)
Number of subjects: 24
Study 11818424 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 45
Study 11818424 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 45
Study 11818424 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study 10959382 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (Ocsaar) 50 mg daily, increased to 100 mg if necessary
Number of subjects: 421
Study 9000839 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin therapy for 3 years
Number of subjects: 0
Study 9000839 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 2201224 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-release dihydrocodeine
Number of subjects: 90
Study 2201224 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release dihydrocodeine
Number of subjects: 90
Study 2201224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7280947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral cefamandole
Number of subjects: 113
Study 7280947 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral penicillin, gentamicin and clindamycin
Number of subjects: 113
Study 7280947 — intervention group
Group type: COMPARATOR
Intervention: No parenteral antibiotics
Number of subjects: 113
Study 29773354 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program (3RP)
Number of subjects: 109
Study 29089058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 195
Study 29089058 — intervention group
Group type: COMPARATOR
Intervention: Fipronil/(S)-methoprene (FSM)
Number of subjects: 195
Study 26078579 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA therapy (50 mL PUFA with 1:1 ratio of EHA and DHA added to daily diet)
Number of subjects: 78
Study 26078579 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA therapy
Number of subjects: 78
Study 26078579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 23566237 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast treatment
Number of subjects: 99
Study 23566237 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (cell culture medium)
Number of subjects: 99
Study 21747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 577
Study 21747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide sustained release
Number of subjects: 577
Study 21747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 577
Study 21747047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 19623052 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise training session for 20 mins/day using a bedside cycle ergometer
Number of subjects: 90
Study 19623052 — intervention group
Group type: COMPARATOR
Intervention: Standardized passive or active motion session of upper and lower limbs (Control group)
Number of subjects: 90
Study 16786420 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist with low-dose hCG protocol (hCGP)
Number of subjects: 192
Study 16786420 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist with no low-dose hCG protocol (NhCGP)
Number of subjects: 192
Study 16786420 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (buserelin) long protocol (LP)
Number of subjects: 192
Study 15475021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity-low-frequency exercise (65-75% HRR, 3-4 sessions/week)
Number of subjects: 324
Study 15475021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity-high-frequency exercise (65-75% HRR, 5-7 sessions/week)
Number of subjects: 324
Study 15475021 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity-high-frequency exercise (45-55% HRR, 5-7 sessions/week)
Number of subjects: 324
Study 15475021 — intervention group
Group type: COMPARATOR
Intervention: High-intensity-high-frequency vs. moderate-intensity-low-frequency
Number of subjects: 324
Study 15475021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity effect on insulin
Number of subjects: 324
Study 15475021 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency effect on aerobic fitness
Number of subjects: 324
Study 11402958 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 0.6 ml/kg (G1)
Number of subjects: 48
Study 11402958 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 1.2 ml/kg (G2)
Number of subjects: 48
Study 11402958 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium and meglumine diatrizoate 58% 0.6 ml/kg (G3)
Number of subjects: 48
Study 11402958 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium and meglumine diatrizoate 58% 1.2 ml/kg (G4)
Number of subjects: 48
Study 9114762 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 296
Study 9114762 — intervention group
Group type: COMPARATOR
Intervention: class I drugs
Number of subjects: 296
Study 9114762 — intervention group
Group type: COMPARATOR
Intervention: class I drugs with beta blockers
Number of subjects: 296
Study 8029263 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg caffeine + 2 mg nicotine polacrilex
Number of subjects: 6
Study 8029263 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine + 4 mg nicotine polacrilex
Number of subjects: 6
Study 8029263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6
Study 8029263 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 6
Study 8029263 — intervention group
Group type: COMPARATOR
Intervention: Nicotine polacrilex
Number of subjects: 6
Study 2918192 — intervention group
Group type: EXPERIMENTAL
Intervention: Written MMSE
Number of subjects: 71
Study 2918192 — intervention group
Group type: COMPARATOR
Intervention: Standard MMSE
Number of subjects: 71
Study 31475622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 23
Study 31475622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30917420 — intervention group
Group type: COMPARATOR
Intervention: HBP-NLVH group (80 cases)
Number of subjects: 240
Study 30917420 — intervention group
Group type: COMPARATOR
Intervention: HBP-LVH group (80 cases)
Number of subjects: 240
Study 30917420 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal control group (80 cases)
Number of subjects: 240
Study 30917420 — intervention group
Group type: COMPARATOR
Intervention: Correlation of microRNA-29b with IVSD
Number of subjects: 240
Study 30917420 — intervention group
Group type: COMPARATOR
Intervention: Correlation of microRNA-29b with LVPWD
Number of subjects: 240
Study 30917420 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity and specificity of serum microRNA-29b levels
Number of subjects: 240
Study 25943992 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase‐associated lipocalin (NGAL)
Number of subjects: 231
Study 25943992 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 231
Study 25943992 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 231